Organization | Swedish Orphan Biovitrum

Swedish Orphan Biovitrum Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Stockholm Sweden (2010)

Status: Acquired by Advent International (2021)

Organization Overview

First Clinical Trial

2010

NCT00070616

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Drugs in Phase 4 Trials (3)

Key: Swedish Orphan Biovitrum (1) Acquired (2)

antihemophilic factor viii (Recombinant) (Adynovate) (3 trials)

avatrombopag (6 trials)

palifermin (kepivance) (14 trials)

Drugs in Phase 3 Trials (14)

Key: Swedish Orphan Biovitrum (12) Acquired (2)

anakinra (kineret) (13 trials)

antihemophilic factor viii human (Hemofil M) (4 trials)

antihemophilic factor viii (Recombinant), Fc-fusion protein (Eloctate) (7 trials)

bile-salt-stimulated lipase (4 trials)

cisplatin (platinol) (2 trials)

coagulation factor ix (Recombinant) (Rixubis) (2 trials)

coagulation factor ix (Recombinant), Fc-fusion protein (Alprolix) (6 trials)

cyclophosphamide (cytoxan) (3 trials)

emapalumab-lzsg (gamifant) (10 trials)

etoposide (vepesid) (1 trial)

human coagulation factor ix (Mononine) (2 trials)

immune globulin (human) (1 trial)

nitisinone (orfadin) (6 trials)

pegcetacoplan (2 trials)

Drugs in Phase 2 Trials (17)

Key: Swedish Orphan Biovitrum (14) Acquired (3)

allogeneic stem cells (1 trial)

axicabtagene ciloleucel (Yescarta) (1 trial)

busulfan (myleran) (1 trial)

bvt.115959 (1 trial)

carboplatin (paraplatin) (1 trial)

endoxan (1 trial)

leuprolide (lupron) (1 trial)

naltrexone (revia) (1 trial)

ni-0101 (1 trial)

ni-0401 (2 trials)

ni-0801 (2 trials)

paclitaxel (taxol) (1 trial)

peripheral blood hematopoietic cell (1 trial)

sobi-003 (2 trials)

symphoglobulin-d (1 trial)

thiotepa (1 trial)

triamcinolone (kenalog) (1 trial)

Drugs in Phase 1 Trials (6)

Key: Swedish Orphan Biovitrum (2) Acquired (4)

cp-870893 (1 trial)

cyanocobalamin (berocca) (1 trial)

heparin (liquaemin) (2 trials)

ni-0701 (1 trial)

ni-1801 (1 trial)

sobi002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Arthritis (Phase 2)

Arthritis, Gouty (Phase 2)

Arthritis, Juvenile (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cystic Fibrosis (Phase 2)

Deglutition Disorders (Phase 2)

Ear Diseases (Phase 2)

Exocrine Pancreatic Insufficiency (Phase 2)

Fibrosis (Phase 2)

Graft vs Host Disease (Phase 2)

Head and Neck Neoplasms (Phase 3)

Hemophilia A (Phase 4)

Hemophilia B (Phase 3)

Infections (Phase 3)

Labyrinth Diseases (Phase 2)

Labyrinthitis (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 4)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 4)

Mucocutaneous Lymph Node Syndrome (Phase 3)

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis III (Phase 3)

Mucositis (Phase 4)

Multiple Myeloma (Phase 4)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 4)

Neuralgia (Phase 2)

Neurotoxicity Syndromes (Phase 2)

Premature Birth (Phase 3)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Signs and Symptoms, Respiratory (Phase 3)

Stevens-Johnson Syndrome (Phase 2)

Still's Disease, Adult-Onset (Phase 3)

Stomatitis (Phase 3)

Tyrosinemias (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 80
# of Trial APIs: 40